The latest update is out from Purple Biotech ( (PPBT) ).
On March 28, 2025, Purple Biotech announced that three of its posters have been accepted for presentation at the 2025 American Association for Cancer Research Meeting, scheduled for April 25-30 in Chicago. These presentations will cover the company’s advancements in cancer treatment, including CM24 for pancreatic cancer and NT219 for colorectal and head and neck cancers. This development highlights Purple Biotech’s ongoing efforts to enhance its position in the oncology market by showcasing its innovative therapies.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance. The company’s oncology pipeline includes CM24, NT219, and CAPTN-3, targeting various cancer indications. Purple Biotech is headquartered in Rehovot, Israel.
YTD Price Performance: -39.98%
Average Trading Volume: 34,463
Technical Sentiment Signal: Hold
Current Market Cap: $7.49M
See more data about PPBT stock on TipRanks’ Stock Analysis page.